| Dr Rachal Michelle Crum, DO | |
|
501 Redmond Rd Nw, Rome, GA 30165-1415 | |
| (706) 291-0291 | |
| Not Available |
| Full Name | Dr Rachal Michelle Crum |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 7 Years |
| Location | 501 Redmond Rd Nw, Rome, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407385511 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fauquier Hospital | Warrenton, VA | Hospital |
| Sentara Northern Virginia Medical Center | Woodbridge, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hospital Physician Services - Southeast Professional Corporation | 5597774554 | 640 |
| Hospital Physician Services - Southeast Professional Corporation | 5597774554 | 640 |
| Southeastern Intensivist Services Pc | 9335152107 | 218 |
| Hospitalist Medicine Physicians Of West Virginia, Pllc | 2860674488 | 63 |
News Archive
MAP Pharmaceuticals, Inc. today reported successful results from a thorough QT trial of its investigational LEVADEX™ orally inhaled migraine therapy. The trial evaluated the potential of a supra-therapeutic dose to cause an increase in the QT interval. Results of the trial showed that a supra-therapeutic dose of LEVADEX does not increase QTc intervals. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.
The work follows a study carried out by Oregon Health and Science University, which suggested a link between a gene mutation in mice and tolerance to alcohol. Researchers at Liverpool have investigated this in worms, looking specifically at the role the gene plays in communication between cells in the nervous system.
New asthma research indicates that as many as a third of people +55 years old may be living with undiagnosed asthma and that a high prevalence of asthma in an ageing population will impose an increasing burden on the health system and the Australian economy in the future.
If you have optimal heart health in middle age, you may live up to 14 years longer, free of cardiovascular disease, than your peers who have two or more cardiovascular disease (CVD) risk factors, according to a new Northwestern Medicine study.
TransTech Pharma, Inc. and High Point Pharmaceuticals, LLC. today announced that they have been awarded cash grants totaling $1.96 million under the U.S. Government's Qualifying Therapeutic Discovery Project program.
› Verified 8 days ago
| Entity Name | Hospital Physician Services - Southeast Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760410385 PECOS PAC ID: 5597774554 Enrollment ID: O20060419000545 |
News Archive
MAP Pharmaceuticals, Inc. today reported successful results from a thorough QT trial of its investigational LEVADEX™ orally inhaled migraine therapy. The trial evaluated the potential of a supra-therapeutic dose to cause an increase in the QT interval. Results of the trial showed that a supra-therapeutic dose of LEVADEX does not increase QTc intervals. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.
The work follows a study carried out by Oregon Health and Science University, which suggested a link between a gene mutation in mice and tolerance to alcohol. Researchers at Liverpool have investigated this in worms, looking specifically at the role the gene plays in communication between cells in the nervous system.
New asthma research indicates that as many as a third of people +55 years old may be living with undiagnosed asthma and that a high prevalence of asthma in an ageing population will impose an increasing burden on the health system and the Australian economy in the future.
If you have optimal heart health in middle age, you may live up to 14 years longer, free of cardiovascular disease, than your peers who have two or more cardiovascular disease (CVD) risk factors, according to a new Northwestern Medicine study.
TransTech Pharma, Inc. and High Point Pharmaceuticals, LLC. today announced that they have been awarded cash grants totaling $1.96 million under the U.S. Government's Qualifying Therapeutic Discovery Project program.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Rachal Michelle Crum, DO 1320 Maplewood Ave, Ronceverte, WV 24970-8016 Ph: (304) 793-2220 | Dr Rachal Michelle Crum, DO 501 Redmond Rd Nw, Rome, GA 30165-1415 Ph: (706) 291-0291 |
News Archive
MAP Pharmaceuticals, Inc. today reported successful results from a thorough QT trial of its investigational LEVADEX™ orally inhaled migraine therapy. The trial evaluated the potential of a supra-therapeutic dose to cause an increase in the QT interval. Results of the trial showed that a supra-therapeutic dose of LEVADEX does not increase QTc intervals. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.
The work follows a study carried out by Oregon Health and Science University, which suggested a link between a gene mutation in mice and tolerance to alcohol. Researchers at Liverpool have investigated this in worms, looking specifically at the role the gene plays in communication between cells in the nervous system.
New asthma research indicates that as many as a third of people +55 years old may be living with undiagnosed asthma and that a high prevalence of asthma in an ageing population will impose an increasing burden on the health system and the Australian economy in the future.
If you have optimal heart health in middle age, you may live up to 14 years longer, free of cardiovascular disease, than your peers who have two or more cardiovascular disease (CVD) risk factors, according to a new Northwestern Medicine study.
TransTech Pharma, Inc. and High Point Pharmaceuticals, LLC. today announced that they have been awarded cash grants totaling $1.96 million under the U.S. Government's Qualifying Therapeutic Discovery Project program.
› Verified 8 days ago
Dr. Gary Killen, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 27 Oakfield Dr Se, Rome, GA 30161 Phone: 706-234-9301 | |
Rachel Marie Risner, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 304 Turner Mccall Blvd Sw, Rome, GA 30165 Phone: 706-509-5000 |